| Ticker Symbol: | MDCO |
|---|---|
| Exchange: | NASD |
| Contact Info: | 8 Campus Drive Parsippany NJ 07054 973 656-1616 |
| CEO/President: | Clive A. Meanwell |
| Industry: | Medical - Biomedical / Standard Industry Code: 2834 |
| Description: | Medicines Company acquires, develops and commercializes biopharmaceutical products in late stages of development. U.S. Food and Drug Administration intends to approve its first product, Angiomax, for use in the treatment ofpatients with unstable angina undergoing coronary balloon angioplasty. The company is also developing Angiomax for additional potential applications for use in the treatment of ischemic heart disease, a condition which occurs when organs receive an inadequate supply of oxygen as a result of decreased blood flow. |
| Shares Outstanding: | 52,080 (000) | Market Value: | 769,770 ($000) |
|---|---|---|---|
| Percentage of Inst.Shareholders: | 95.06% | Number of Inst.Shareholders: | 4.70% |
| Last Quarter Sales: | 88.13 ($Mil.) | Last Quarter Net Income: | -13.22 ($Mil.) |
| Last Quarter EPS: | 0.00 | P/E Ratio: | 74 |
| Most Recent Earnings: | 0.05 on 10/22/08 | Earnings Per Share: | -0.05 |
| Most Recent Split: | Annual Dividend Rate: | 0 | |
| Most Recent Dividend: | Annual Dividend Yield: | 0% |

| AMGEN INC. | +9.10 | 56.09 | |
| GILEAD SCIENCES | -1.80 | 45.91 | |
| CELGENE CORPORA | -8.00 | 58.56 | |
| BIOGEN IDEC INC | -31.90 | 43.13 | |
| STEMCELLS INC. | -56.40 | 1.23 |
